Abbott Laboratories (ABT) Market Cap & Valuation Ratios
Abbott Laboratories (ABT) has a market cap of $179.4B, a trailing P/E of 33.5 and a price-to-sales ratio of 3.9, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ABTAbbott LaboratoriesFollow ABT — free
—
Price chart with a free account
- Market cap
- 179.4B
- P/E TTM
- 33.5
- Dividend yield
- 2.4%
- 52-week
- —
- Next earnings
- 20 Jan, in 88 days
Peers
medical devices · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| ABT | 179 | 33.5 | 4.4 | 19.1 | 4.4% | +8% | 16% | 8% |
| MDT | 122 | 23.4 | 3.8 | 14.5 | 5.0% | +10% | 18% | 7% |
| SYK | 118 | 31.8 | 5.0 | 18.1 | 4.0% | +8% | 21% | 11% |
| BSX | 66 | 18.5 | 3.7 | 14.1 | 5.5% | +14% | 20% | 11% |
| EW | 51 | 51.2 | 7.3 | 29.5 | 2.8% | +15% | 22% | 12% |
| GEHC | 32 | 16.4 | 1.9 | 12.1 | 4.9% | +7% | 13% | 12% |
| DXCM | 29 | 30.9 | 5.9 | 21.1 | 4.8% | +16% | 23% | 33% |
| STE | 23 | 28.4 | 4.0 | 14.7 | 4.1% | +8% | 19% | 10% |
| ZBH | 19 | 23.9 | 3.0 | 11.2 | 6.4% | +9% | 14% | 5% |
| PEN | 13 | 79.7 | 8.1 | 59.3 | 1.7% | +18% | 12% | 13% |
| GMED | 11 | 20.9 | 3.3 | 11.2 | 6.9% | +20% | 20% | 12% |
| Median of these 10 | 26.1 | 3.9 | 14.6 | 4.8% | +12% | 19% | 12% |
P/E 33.5 vs. a peer median of 26.1; EV/Sales 4.4 vs. 3.9. ABT's own P/E sits at the 73rd percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesHover or tap a dot for values.
Abbott Laboratories — questions
- What is Abbott Laboratories's market cap?
- $179.4B.
- What is Abbott Laboratories's P/E ratio?
- 33.5 on trailing twelve-month earnings to 2026-06-30.
- What is Abbott Laboratories's price-to-sales ratio?
- 3.9.
Every figure on this page comes from Abbott Laboratories's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.